Subcutaneous treprostinil in congenital heart disease-related pulmonary arterial hypertension

OBJECTIVE: To assess the efficacy and safety of subcutaneous treprostinil in adult patients with congenital heart disease (CHD)-associated pulmonary arterial hypertension (PAH) after 12 months of treatment. METHODS: Consecutive adult patients with CHD–PAH received subcutaneous treprostinil to maximu...

Descripción completa

Detalles Bibliográficos
Autores principales: Skoro-Sajer, Nika, Gerges, Christian, Balint, Olga Hajnalka, Kohalmi, Dora, Kaldararova, Monika, Simkova, Iveta, Jakowitsch, Johannes, Gabriel, Harald, Baumgartner, Helmut, Gerges, Mario, Sadushi-Kolici, Roela, Celermajer, David S, Lang, Irene Marthe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Congenital Heart Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6047165/
https://www.ncbi.nlm.nih.gov/pubmed/29436381
http://dx.doi.org/10.1136/heartjnl-2017-312143

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6047165/
https://www.ncbi.nlm.nih.gov/pubmed/29436381
http://dx.doi.org/10.1136/heartjnl-2017-312143

Ejemplares similares